- Report
- April 2025
- 279 Pages
Global
From €5249EUR$5,850USD£4,518GBP
- Report
- April 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 139 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- October 2023
- 104 Pages
Global
From €3500EUR$4,178USD£3,118GBP
- Report
- May 2023
- 91 Pages
Global
From €3500EUR$4,178USD£3,118GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Book
- July 2023
- 1568 Pages
- Book
- July 2015
- 328 Pages
Albendazole is an anthelmintic drug used to treat a variety of parasitic infections caused by nematodes, cestodes, and trematodes. It is commonly used to treat infections such as ascariasis, trichuriasis, and hookworm infections. Albendazole is also used to treat cystic hydatid disease, a condition caused by the larvae of the tapeworm Echinococcus granulosus. It is available in both oral and intravenous forms.
Albendazole is a widely used drug in the treatment of infectious diseases. It is effective against a variety of parasites, including those that cause intestinal infections, and is well tolerated by patients. It is also used to treat cystic hydatid disease, a condition caused by the larvae of the tapeworm Echinococcus granulosus.
The Albendazole market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi-Aventis, Pfizer, and Novartis. Other companies include Cipla, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more